REG - Smith & Nephew Plc - Director/PDMR Shareholding
13/03/2024 16:15
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240313:nRSM7513Ga&default-theme=true
RNS Number : 7513G Smith & Nephew Plc 13 March 2024
SMITH & NEPHEW PLC
13 March 2024
NOTIFICATION AND PUBLIC DISCLOSURE IN ACCORDANCE WITH THE REQUIREMENTS OF THE
EU MARKET ABUSE REGULATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL
RESPONSIBILITIES ("PDMR") AND PERSONS CLOSELY ASSOCIATED WITH THEM.
1. VESTING OF SHARE AWARDS UNDER THE GLOBAL SHARE PLAN 2020
On 13 March 2024, the Company received notification of the following
transactions in US$0.20 ordinary shares (the "Shares") in Smith & Nephew
plc (the "Company") following the vesting of awards under the Smith &
Nephew Global Share Plan 2020.
i. VESTING OF 2021 PERFORMANCE SHARE PROGRAMME AWARDS MADE UNDER THE SMITH
& NEPHEW GLOBAL SHARE PLAN 2020:
The awards were granted under the Global Share Plan 2020 on 21 May 2021, and
vested on 11 March 2024 at 21% of target for those employees who were members
of the Company's Executive Committee when the award was granted and at 33.58%
for all other senior employees who received an award. A number of Shares
were sold to cover taxation obligations arising on the vesting of the awards.
The number of Shares acquired includes the dividend equivalent Shares which
participants receive on vested Shares. The table below sets out the number
of shares under award which vested. The remaining shares under award have
lapsed.
The following relates to individuals included in the below notification:
Reason for the notification
Initial notification /Amendment Initial notification
Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
Name Smith & Nephew plc
LEI 213800ZTMDN8S67S1H61
Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
Description of the financial instrument, type of instrument Smith & Nephew plc ordinary shares of USD 0.20 each
Identification code ISIN: GB0009223206
Nature of the transaction Vesting of Smith & Nephew Global Share Plan 2020: Performance Share
Programme awards granted on 21 May 2021, and subsequent sale of shares to
cover tax liability
Date of Transaction 2024 - 03 - 11 (vesting) and 2024 - 03 - 12 (market sale)
Place of Transaction London Stock Exchange (XLON)
Name Price (£) Volume Aggregated information
(Position) Status
Helen Barraclough(1) PDMR 11.079467 2,443 (of which 1,154 were sold and 1,289 retained.) N/A Single Transaction
(Group General Counsel and Company Secretary)
Bradley Cannon(2) PDMR 11.079467 12,852 (of which 4,416 were sold and 8,436 retained.) N/A Single Transaction
(President, Orthopaedics & Americas)
Phil Cowdy(2) PDMR 11.079467 5,736 (of which 2,707 were sold and 3,029 retained.) N/A Single Transaction
(Chief Corporate Development and Corporate Affairs Officer)
Craig Gaffin(1) PDMR 11.079467 2,067 (of which 616 were sold and 1,451 retained.) N/A Single Transaction
President, Global Orthopaedics
Elga Lohler(2) PDMR 11.079467 7,308 (of which 2,891 were sold and 4,417 retained.) N/A Single Transaction
(Chief HR Officer)
Vasant Padmanabhan(2) PDMR 11.079467 7,161 (of which 2,875 were sold and 4,286 retained.) N/A Single Transaction
(President Research & Development ENT)
Scott Schaffner(1) PDMR 11.079467 3,733 (of which 1,112 were sold and 2,621 retained.) N/A Single Transaction
(President Sports Medicine)
(1)Award vested at 33.58%
(2)Award vested at 21.00%
All figures in these columns are stated to 6 decimal places where applicable.
ii. FINAL VESTING OF 2021 EQUITY INCENTIVE PROGRAMME AWARDS MADE UNDER THE
GLOBAL SHARE PLAN 2020:
The awards were granted under the Global Share Plan 2020 on 9 March 2021. One
third of the Shares vested on 9 March 2022, a further third vested on 9 March
2023 and the final third vested on 11 March 2024. A number of Shares were sold
to cover taxation obligations arising on the vesting of the awards. The number
of Shares acquired includes the dividend equivalent Shares which participants
receive on vested Shares.
The following relates to individuals included in the below notification:
Reason for the notification
Initial notification /Amendment Initial notification
Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
Name Smith & Nephew plc
LEI 213800ZTMDN8S67S1H61
Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
Description of the financial instrument, type of instrument Smith & Nephew plc ordinary shares of USD 0.20 each
Identification code ISIN: GB0009223206
Nature of the transaction Final vesting on 11 March 2024 of Equity Incentive Programme awards granted on
9 March 2021 under the Smith & Nephew Global Share Plan 2020, and
subsequent sale of shares to cover tax liability
Date of Transaction 2024 - 03 - 11 (vesting) and 2024 - 03 - 12 (market sale)
Place of Transaction London Stock Exchange (XLON)
Name Price (£) Volume Aggregated information
(Position) Status
Helen Barraclough PDMR 11.079467 3,105 (of which 1,465 were sold and 1,640 retained.) N/A Single Transaction
(Group General Counsel and Company Secretary)
Bradley Cannon PDMR 11.079467 7,082 (of which 2,432 were sold and 4,650 retained.) N/A Single Transaction
(President, Orthopaedics & Americas)
Phil Cowdy PDMR 11.079467 5,679 (of which 2,679 were sold and 3,000 retained.) N/A Single Transaction
(Chief Corporate Development and Corporate Affairs Officer)
Elga Lohler PDMR 11.079467 6,328 (of which 2,502 were sold and 3,826 retained.) N/A Single Transaction
(Chief HR Officer)
Vasant Padmanabhan PDMR 11.079467 5,246 (of which 2,106 were sold and 3,140 retained.) N/A Single Transaction
(President Research & Development ENT)
Scott Schaffner PDMR 11.079467 3,562 (of which 1,060 were sold and 2,502 retained.) N/A Single Transaction
(President Sports Medicine)
All figures in these columns are stated to 6 decimal places where applicable.
iii. PARTIAL VESTING OF 2022 DEFERRED BONUS SHARE AWARDS MADE UNDER THE
GLOBAL SHARE PLAN 2020:
The awards were granted under the Global Share Plan 2020 on 9 March 2022. One
third of the Shares vested on 9 March 2023, a further third vested on 11 March
2024 and the final third will vest on 10 March 2025. A number of Shares were
sold to cover taxation obligations arising on the vesting of the awards. The
number of Shares acquired includes the dividend equivalent Shares which
participants receive on vested Shares.
The following relates to individuals included in the below notification:
Reason for the notification
Initial notification /Amendment Initial notification
Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
Name Smith & Nephew plc
LEI 213800ZTMDN8S67S1H61
Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
Description of the financial instrument, type of instrument Smith & Nephew plc ordinary shares of USD 0.20 each
Identification code ISIN: GB0009223206
Nature of the transaction Partial vesting on 11 March 2024 of Deferred Bonus Share awards, granted on 9
March 2022 under the Smith & Nephew Global Share Plan 2020, and subsequent
sale of shares to cover tax liability
Date of Transaction 2024 - 03 - 11 (vesting) and 2024 - 03 - 12 (market sale)
Place of Transaction London Stock Exchange (XLON)
Name Price (£) Volume Aggregated information
(Position) Status
Helen Barraclough PDMR 11.079467 1,769 (of which 834 were sold and 935 retained.) N/A Single Transaction
(Group General Counsel and Company Secretary)
Bradley Cannon PDMR 11.079467 6,418 (of which 2,205 were sold and 4,213 retained.) N/A Single Transaction
(President, Orthopaedics & Americas)
Phil Cowdy PDMR 11.079467 2,900 (of which 1,368 were sold and 1,532 retained.) N/A Single Transaction
(Chief Corporate Development and Corporate Affairs Officer)
Craig Gaffin PDMR 11.079467 873 (of which 260 were sold and 613 retained.) N/A Single Transaction
President, Global Orthopaedics
Mizanu Kebede PDMR 11.079467 734 (of which 273 were sold and 461 retained.) N/A Single Transaction
(Chief Quality & Regulatory Affairs Officer)
Elga Lohler PDMR 11.079467 4,139 (of which 1,637 were sold and 2,502 retained.) N/A Single Transaction
(Chief HR Officer)
Vasant Padmanabhan PDMR 11.079467 3,348 (of which 1,344 were sold and 2,004 retained.) N/A Single Transaction
(President Research & Development ENT)
Scott Schaffner PDMR 11.079467 2,433 (of which 724 were sold and 1,709 retained.) N/A Single Transaction
(President Sports Medicine)
All figures in these columns are stated to 6 decimal places where applicable.
iv. PARTIAL VESTING OF 2023 DEFERRED BONUS SHARE AWARDS MADE UNDER THE
GLOBAL SHARE PLAN 2020:
The awards were granted under the Global Share Plan 2020 on 9 March 2023. One
third of the Shares vested on 11 March 2024, a further third will vest on 10
March 2025 and the final third will vest on 9 March 2026. A number of Shares
were sold to cover taxation obligations arising on the vesting of the awards.
The number of Shares acquired includes the dividend equivalent Shares which
participants receive on vested Shares.
The following relates to individuals included in the below notification:
Reason for the notification
Initial notification /Amendment Initial notification
Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
Name Smith & Nephew plc
LEI 213800ZTMDN8S67S1H61
Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
Description of the financial instrument, type of instrument Smith & Nephew plc ordinary shares of USD 0.20 each
Identification code ISIN: GB0009223206
Nature of the transaction Partial vesting on 11 March 2024 of Deferred Bonus Share awards, granted on 9
March 2023 under the Smith & Nephew Global Share Plan 2020, and subsequent
sale of shares to cover tax liability
Date of Transaction 2024 - 03 - 11 (vesting) and 2024 - 03 - 12 (market sale)
Place of Transaction London Stock Exchange (XLON)
Name Price (£) Volume Aggregated information
(Position) Status
Helen Barraclough PDMR 11.079467 1,714 (of which 809 were sold and 905 retained.) N/A Single Transaction
(Group General Counsel and Company Secretary)
Bradley Cannon PDMR 11.079467 2,818 (of which 968 were sold and 1,850 retained.) N/A Single Transaction
(President, Orthopaedics & Americas)
Paul Connolly PDMR 11.079467 1,943 (of which 662 were sold and 1,281 retained.) N/A Single Transaction
(President, Global Operations)
Phil Cowdy PDMR 11.079467 1,847 (of which 871 were sold and 976 retained.) N/A Single Transaction
(Chief Corporate Development and Corporate Affairs Officer)
Craig Gaffin PDMR 11.079467 574 (of which 171 were sold and 403 retained.) N/A Single Transaction
President, Global Orthopaedics
Mizanu Kebede PDMR 11.079467 1,987 (of which 738 were sold and 1,249 retained.) N/A Single Transaction
(Chief Quality & Regulatory Affairs Officer)
Elga Lohler PDMR 11.079467 2,907 (of which 1,149 were sold and 1,758 retained.) N/A Single Transaction
(Chief HR Officer)
Vasant Padmanabhan PDMR 11.079467 2,365 (of which 949 were sold and 1,416 retained.) N/A Single Transaction
(President Research & Development ENT)
Alison Parkes PDMR 11.079467 1,028 (of which 486 were sold and 542 retained.) N/A Single Transaction
(Chief Compliance Officer)
Scott Schaffner PDMR 11.079467 949 (of which 283 were sold and 666 retained.) N/A Single Transaction
(President Sports Medicine)
All figures in these columns are stated to 6 decimal places where applicable.
Sarah Carne
Deputy Company Secretary
Smith & Nephew plc
Tel: +44 (0)1923 477100
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHFLFEEVAIVLISRecent news on Smith & Nephew
See all newsREG - Smith & Nephew Plc - Timing of Smith+Nephew Q1 2024 Trading Report
AnnouncementREG - Smith & Nephew Plc - Total Voting Rights
AnnouncementREG - Smith & Nephew Plc - Director/PDMR Shareholding
AnnouncementREG - Smith & Nephew Plc - Directorate Change
AnnouncementREG - Smith & Nephew Plc - SMITH+NEPHEW PRICES USD BOND ISSUE
Announcement